Contents. Approved by: Kent Lewandrowski, M.D. 6/1/2005 Written/Updated by: Gino Pagnani Date: 4/3/09

Similar documents
JOHN H. STROGER HOSPITAL OF COOK COUNTY ANNUAL TRAINING HEMOCCULT

Written By: Joann O Connor Date: 01/27/2017 Effective Date: 02/22/2017 1

HARBOR-UCLA MEDICAL CENTER Torrance, California DEPARTMENT OF EMERGENCY MEDICINE POLICY AND PROCEDURE MANUAL

REFERENCES HemaPrompt FG Product Information. June, Aerscher Diagnostics, Chestertown, MD.

Discussion. Points: 20. Objectives:

CLIA Complexity: WAIVED INTENDED USE SUMMARY AND EXPLANATION

Rapid-VIDITEST FOB Blister

CLIA Complexity: Waived

PROCEDURE MANUAL. Prepared By Date Adopted Supersedes Procedure # Review Date Revision Date Signature

CLIA Complexity: WAIVED

CHEMSTRIP 10 Urine Test Strips * READ POLICY PRIOR TO STARTING TUTORIAL

Collecting Stool Specimens for Culture Collecting Stool Specimens For Parasitology Collection of 72 Hour Stool Fat

PROCEDURE. Sekisui Diagnostics OSOM ifob Rapid Test. Title: Procedure #: Institution: Prepared by: Date: Title: Accepted by: Date adopted: Title:

Helicobacter pylori Antigen Test

We couldn t have made it any easier.

Rapid-VIDITEST Calprotectin

Type Description Date Version Performed By Notes

Rapid-VIDITEST. FOB+Tf. One step Fecal Occult Blood Card Test. Instruction manual

Strep-a-Test Twister Test

Rotavirus Test Kit. Instructions For Use. Format: Cassette Specimen: Fecal Extract Catalog Number: VEL-001-ROTA

Rapid-VIDITEST. Helicobacter pylori. One step Helicobacter pylori Blister test. Instruction manual

CHEMSTRIP 7 - URINE TEST STRIP

ifob Test Rev. P5576-A, 04/16 5. Read the result in 5-10 minutes. RESULTS AFTER 10 MINUTES. Important: DO NOT READ

Hepatitis C Virus (HCV) Antibody Test

Human Influenza A (Swine Flu) Rapid test

Rapid-VIDITEST C. difficile Ag (GDH) Card/Blister

MARSHALLTOWN MEDICAL & SURGICAL CENTER Marshalltown, Iowa

Step-by-Step Instructions For OraQuick HCV Rapid Antibody Test

ifob Test Rev. P /15 6. Read the result in 5-10 minutes. RESULTS AFTER 10 MINUTES. Important: DO NOT READ

To provide you with necessary knowledge and skills to accurately perform 3 HIV rapid tests and to determine HIV status.

Management of Central Venous Access Devices. Blood Glucose Monitoring

NexScreen Cup. Urine Drug Screen * READ POLICY PRIOR TO STARTING TUTORIAL

Rapid-VIDITEST Swine Flu

Treponema Pallidum (TP) Antibody Test

TB LAM Ag Lateral Flow Assay Standard Operating Procedure

INSTANT-VIEW H. pylori Rapid Test CLIA WAIVED Test for Whole Blood QUALITATIVE IN-VITRO DIAGNOSTIC TEST FOR EXTERNAL USE ONLY

Stool Collection Guidelines

Rapid-VIDITEST. Astrovirus Card

Summary of Significant Changes at this Revision. Items Required. Printed copies are uncontrolled unless there is an allocated Copy Number on page 1

WHO Prequalification of Diagnostics Programme PUBLIC REPORT

NEGATIVE POSITIVE. Rev , 06/11. 5 min. Mono Test. For fi ngertip. blood: 1 DROP 1 DROP For serum, whole blood. plasma or. samples.

PROCEDURE MANUAL. Prepared By Date Adopted Supersedes Procedure # Review Date Revision Date Signature

QUICK REFERENCE INSTRUCTIONS. THYROCHEK TSH Cassette

T R A I N I N G G U I D E

CDIA TM Rubella IgG/IgM Rapid Test Kit

Rapid-VIDITEST. Strep A Card. One step Strep A Card for the detection of Group A Streptococcal antigen from throat swabs or culture.

Point of Care Testing for INR using CoaguChek XS Plus

DETERMINE SPECIMEN REQUIREMENTS HIV-1/2 Ag/Ab Combo TESTING PROCEDURE

Rapid-VIDITEST. Calprotectin-Lactoferrin

biorapid FOBT 20 Test cod

Chlamydia trachomatis (CHLa)Test Kit

Rapid-VIDITEST Enterovirus

MARSHALLTOWN MEDICAL & SURGICAL CENTER Marshalltown, Iowa

ANTIBODY SCREENING by Uni-Gold Recombigen HIV

DRG FIV Ab Rapid Test (RAP-4801 / RAP-4821)

Precision Xtra Training

Rapid-VIDITEST. Rota-Adeno Blister. One Step Rotavirus and Adenovirus Antigen Blister test. Instruction manual

Mono Test 1 DROP 1 DROP. For fingertip blood: For serum, plasma or whole blood samples in tubes: Rev , 05/09

TITLE: Whole Blood Glucose Monitoring Using the Nova StatStrip Meter

SAMPLE PROCEDURE , 07/11

Rapid-VIDITEST. Strep A Blister. One step Strep A Blister for the detection of Group A Streptococcal antigen from throat swabs or culture.

OratectPlus Oral Fluid Drug and Alcohol Screen Device Training and Certification Program

Influenza A & B Screening

Rapid-VIDITEST Shigella dysenteriae

Summary of Significant Changes at this Revision. Items Required

Items in the package:

Tips for Training New Customers

PROCEDURE NO. POC LBH. Printed copies are for reference only. Please refer to the electronic copy for the latest version.

Controls (positive and negative) for quality assessment-located in central laboratory Note: See central lab UA procedure for QC. Read strips visually.

CrAg Lateral Flow Assay Standard Operating Procedure

PROFICIENCY TESTING POLICY

HAV IgG/IgM Rapid Test

Urinalysis and Body Fluids CRg. Feces. Feces. Unit 5. 5 Feces & miscellaneous handouts draft

Rubella Latex Agglutination Test

BÜHLMANN fcal turbo. Calprotectin turbidimetric assay for professional use. Reagent Kit B-KCAL-RSET. Revision date:

USO PROFESSIONALE PROFESSIONAL USE

Malaria Pf/pan antigen Rapid Test

Determination of Vitamin C in Fruit Juices

Colorectal Cancer Screening. Dr Kishor Muniyappa 2626 Care Drive, Suite 101 Tallahassee, FL Ph:

Version No.: 5.0 TITLE: SDS FOR FECAL OCCULT BLOOD TEST KIT T1-CK SERIES Page 1 of 5

SOLUTION TEST STRIPS

Rapid-VIDITEST. Influenza A+B

Stepwise Process for Improving the Quality of HIV-related POCT Sites Towards Certification

HemoCue Hb METHOD AND SAMPLE COLLECTION

SAMPLE PROCEDURE 907-9, 06/11

IVD Revised 22 July, 2008

Precision ceedpro. Online Training for. Glucometer & Capillary Collection

HBeAg and HBeAg Ab ELISA Kit

Rapid-VIDITEST. Influenza A

Title: Abbott Optium Xceed Glucose Meter Effective date: 16/05/2011. Summary of Significant Changes at this Revision. SOP updated.

Point of Care (POC) Glucose Testing Revised on: December, 2018 Reference: Policy LAB 23-A; Point of Care Nova Stat Strip Glucose Meter

ACTG Laboratory Technologist Committee Revised Version 2.0 ACTG Lab Man Coulter HIV-1 p24 ELISA May 21, 2004

SPECIMEN COLLECTION-WAIVED TESTING

SAMPLE PROCEDURE , 07/11

FECAL OCCULT BLOOD TEST (FOBT) Common Guaiac versus Immunochemical Test

Perform extraction for finished product, rinse water or swab. Transfer 12 drops of extract to incubation vial.

NJ RAPID HIV TESTING SUPPORT PROGRAM

IVD information *Droppers for the sensitized and control cells. Not for use other than dispensing the sensitized and control cells.

Product Training & Certification

Transcription:

POCT Program Massachusetts General Hospital - Pathology Service 55 Fruit Street, Boston, MA 02114 Title: Hemoccult Sensa Fecal Occult Blood Procedure Cross References: Hemoccult Sensa Fecal Occult Blood Training and Competency Record Hemoccult Sensa Outpatient Patient Result-QC log Hemoccult Sensa Patient Care Services QC Log Hemoccult Sensa Slides and Developer Lot Documentation MGH POCT QC Storage Ordering and Documentation Guide Hemoccult Sensa Job Aid Contents Purpose... 2 Scope... 2 Policy and Procedure Statement... 2 Regulatory Requirements... 2 Critical Elements... 3 Limitations/Interferences... 3 Test Kit/Supplies/Equipment... 3 Storage and Stability... 4 Specimen Collection... 4 Test Procedure... 4 Interpretation of the Hemoccult Sensa Test... 4 Performance Monitor Feature (Quality Control Monitoring)... 5 Hemoccult Sensa Slides and Developer Lot Documentation... 5 Reference Range... 5 Documentation... 5 Training/Competency Assessment... 6 References... 6 Cross - References... 6 Approved by: Kent Lewandrowski, M.D. 6/1/2005 Written/Updated by: Gino Pagnani Date: 4/3/09 1

Purpose This document outlines policies and procedures that deal with fecal occult blood testing. In an effort to be concise, some information may be excluded from the manufacturer s recommended procedure. It is recommended that operators familiarize themselves with the manufacturer s product information that accompanies each package and their manual if one exists. Scope Level of Personnel: All RNs, NPs, PCAs, MAs, who have successfully completed initial training and maintained annual competency. Testing Site: All sites approved and on file with the Department of Pathology s POCT Division. Policy and Procedure Statement Hemoccult Sensa Test Kits are used as a routine colo-screening test for the qualitative detection of fecal occult blood, which may be an indication of gastrointestinal disease. It is NOT a test for colorectal cancer or other specific diseases. The manufacturer recommends this test for professional use as a diagnostic aid during routine physical exams for hospital patients, to monitor bleeding in patients with iron deficiency anemia or recuperating from surgery, peptic ulcer, ulcerative colitis and other conditions, and screening programs for colorectal cancer when Patient Instructions are followed (See Manufacturers Product Instructions). Additional information can be found on the manufacturer s insert provided with each box of slides. Regulatory Requirements I. Each testing site must have a documented quality control program, which is developed in collaboration with or has been approved by the MGH Pathology Service. II. All test results must be maintained in patient records with all required information for four years Required information: 1. Patient s name 2. Medical Record Number 3. Patient s gender 4. Patient s age or date of birth 5. Date & time test collected, performed and reported 6. Ordering Physician 7. Responsible physician (if not 6) 8. Reference or Target Range 9. Test Performed 10. Test units 11. Lab name III. Additional information that must be retained for four years: 1. Testing personnel records 2. Quality control results 3. Product information (i.e. serial number, lot numbers, expiration dates, etc.), information on quality control and any remedial action 4. QC charts, maintenance sheets, reference and critical ranges IV. Other 1. Universal precautions must be observed when handling any patient specimen. 2. A physician s order or standing order is required prior to performing test. 2

3. The Hospital Hand Hygiene policy must be adhered to at all times. Critical Elements 1. The On Slide Performance Monitor is performed on each slide after patient testing. 2. Do not use Hemoccult Sensa testing for gastric testing. 3. Only approved lots obtained through Materials Management/O&M may be used with this procedure. Limitations/Interferences Interfering substances In general, patients should be carefully instructed to not ingest foods and vitamins that can cause false positive or false-negative test results for at least 72 hours before and through the test period. 1. Substances that can cause false-positive test results: Red meat (beef, lamb, and liver) Aspirin (greater than 325 mg/day) and other non-steroidal anti-inflammatory drugs such as ibuprofen, indomethacin and naproxen Corticosteroids, phenylbutazone, reserpine, anticoagulants, antimetabolites, and cancer chemotherapeutic drugs Alcohol in excess The application of antiseptic preparations containing iodine (povidone/iodine mixture) A high bile content may cause the feces to appear green. A distinct green color (no blue), appearing on or at the edge of the smear within 60 seconds after adding the developer, should be interpreted as negative for occult blood. Dietary iron supplements will not produce false-positive test results with Hemoccult SENSA tests. Acetaminophen is not expected to affect test results. 2. Substances that can cause false-negative test results: Ascorbic acid (vitamin C) in excess of 250 mg per day Excessive amounts of vitamin C-enriched foods such as citrus fruits and juices Iron supplements which contain quantities of vitamin C in excess of 250 mg per day Occasionally, a light blue discoloration may be noticed on the guaiac test paper. This discoloration does not affect the accuracy or performance of the test when it is developed and interpreted according to the recommended procedure. When developer is added directly over the fecal smear on a discolored slide, the blue background color migrates outward and a blue ring forms at the edge of the wetted area, leaving the guaiac paper around the fecal smear off-white in color. Any blue on or at the edge of the smear is positive for Hemoccult blood. Test Kit/Supplies/Equipment Products Vendor Manufacturer # Instant-Recall Memory Timer Fisher Scientific People Soft# Fisher #: 02-401-7 Storage Comments Hemoccult Sensa Slide Hemoccult Sensa Developer O&M# 5891-64151PHC O&M# 5891-64115PHC 64151PHC 20363 RT (15-30 C,59-86 F) 64115PHC 20374 RT (15-30 C,59-86 F) Packaged as single cards no developer Individual bottles of developer Hemoccult Sensa Dispensapak Plus O&M# 5891-64130PHC 64130PHC 028114 RT (15-30 C,59-86 F) Packaged as triple card sets for patient home use; has two bottles of developer 3

Materials supplied in the Hemoccult Sensa DIspensapak Plus: 1. Hemoccult SENSA Slides (blue striped) 2. Hemoccult SENSA Developer (blue cap and striped label) 3. Applicator sticks 4. Patient envelopes with patient sample collection instructions (Hemoccult SENSA Dispensapak Plus) 5. Mailing pouch for returning slides (Hemoccult SENSA Dispensapak Plus) 6. Collection tissues (Hemoccult SENSA Dispensapak Plus) 7. Hemoccult SENSA product instructions Storage and Stability Do not refrigerate or freeze. Slides should be protected from extreme heat and light or volatile chemicals (e.g., iodine, chlorine, bromine, or ammonia. The Hemoccult Sensa Slides and Developer will remain stable until the expiration dates which appear on each slide and developer bottle when stored as recommended appear on each slide and developer bottle when stored as recommended. Specimen Collection Label fecal occult blood card with two patient identifiers per hospital policy. Collect a small fecal sample on the end of applicator stick. Test Procedure Check the expiration date of the developer before using. 1. Identification (two identifiers required): Before opening the slide label with patient s name and/or date of birth and patient medical record number 2. Follow hand hygiene protocol and put on gloves. 3. Preparing the Test: Using applicator provided, collect small fecal sample. Apply a THIN smear inside Box A with the applicator stick Reuse applicator to obtain second sample from a different part of feces Apply thin smear covering Box B Close cover flap. Dispose of applicator in waste container. 4. Developing the Test: 5. Wait 3-4 minutes before applying the developer Using applicator provide 6. Open flap on backside of slide and apply 2 drops of Hemoccult Sensa Developer to the guaiac paper directly over each smear. Read patient results within 60 seconds! Interpretation of the Hemoccult Sensa Test 1. Negative Smears (fig. 1) Applicator stick No detectable blue on or at the edge of the smears indicates the test is negative for occult blood. 2. Positive Smears (fig. 2) Any trace of blue on or at the edge of one or more of the smears indicates the test is positive for occult blood. Negative (fig.1) Positive (fig.2) 4

Do not report any results unless the On Slide Performance Monitor produces an acceptable result. Document the Performance Monitor results on the Patient/Quality Control log sheet. Performance Monitor Feature (Quality Control Monitoring) The function and stability of the slides and developer must be tested using the On Slide Performance Monitor (fig. 4). It is performed on EVERY SLIDE as part of the test procedure. The positive (+) and negative (-) Performance Monitor areas are located under the sample area on the developing side of the slides. Procedure to develop performance monitor: 1. Apply ONE DROP ONLY of Hemoccult Sensa Developer BETWEEN the (+) and (-) Performance Monitor areas. 2. Read the Performance Monitor results within 10 seconds: a BLUE color will appear in the (+) area, and NO BLUE will appear in the (-) area if the kit is functional. 3. If neither occurs, discard the slide and repeat the test using another slide. If the problem reoccurs, try the following: Repeat the test using a new developer Repeat the test using a card and developer from a new box (verifying first that it is an approved lot). Notify the POCT Coordinators by pager 35058 or email at mghpoctcoordinators. Positive: A blue color will appear within 10 seconds after application of developer and remain stable for at least 60 seconds if the test system is functional. The positive Performance Monitor area contains a hemoglobin-derived catalyst, which will turn blue within 10 seconds after applying developer. Negative: No blue color should appear after application of developer if the test system is functional. The negative performance Monitor area contains no such catalyst and should not turn blue after applying developer. On Slide Performance Monitor (fig. 4). Any blue originating from the Performance Monitor areas should be ignored when reading the specimen test results. Neither the intensity nor the shade of the blue from the positive Performance Monitor areas, as illustrated, should be used as a reference for the appearance of positive test results. The Performance Monitor feature provides assurance that the fecal occult blood paper and developer are functional. In the unlikely event that the Performance Monitor areas do not react as expected after applying developer, the results should be regarded as invalid. Should this occur, contact the POCT Coordinators by pager 35058 or email at mghpoctcoordinators. Only those patient results that have demonstrated acceptable On Slide Performance are to be accepted and acted upon. The Performance monitor results must be documented concurrently on the patient s chart or the QC log sheet. Hemoccult Sensa Slides and Developer Lot Documentation A single lot of slides and developer is sequestered at Owens and Minor for use at MGH. When a new lot is received, the POCT Coordinators are notified. The procedural controls on the Hemoccult cards are documented with each test and are considered the same as external controls. External validation of the cards is not required. Reference Range Patient test: Negative Documentation The patient s results and the Performance monitor results must be recorded concurrently in one of the following manners: 5

1. in the patient s record, or 2. on Fecal Occult Blood Patient/ QC log or 3. on another approved permanent record. All records must be retained and retrievable for 4 years. Training/Competency Assessment Competency is assessed after initial training and annually using at least two of the following methods: 1. Performing a test on a blind specimen. 2. Supervisor observes performance of routine work. 3. Each user s quality control performance is monitored. 4. Written testing specific to the method. References Hemoccult Sensa Slide package insert. Beckman Coulter Inc. 4300 N. Harbor Blvd. Fullerton, CA 92834-3100 www.beckmancoulter.com/pcd Cross - References Hemoccult Sensa Fecal Occult Blood Training and Competency Record Hemoccult Sensa Slides and Developer Lot Documentation Hemoccult Sensa Slides Outpatient Result-Quality Control Log Hemoccult Sensa Patient Care Services QC Log 6